523 related articles for article (PubMed ID: 29733945)
1. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
2. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
Battelli MG; Polito L; Bolognesi A
Atherosclerosis; 2014 Dec; 237(2):562-7. PubMed ID: 25463089
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Redox Biol; 2019 Feb; 21():101070. PubMed ID: 30576922
[TBL] [Abstract][Full Text] [Related]
4. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
5. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
6. Xanthine oxidoreductase in cancer: more than a differentiation marker.
Battelli MG; Polito L; Bortolotti M; Bolognesi A
Cancer Med; 2016 Mar; 5(3):546-57. PubMed ID: 26687331
[TBL] [Abstract][Full Text] [Related]
7. Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update.
Mudgal R; Singh S
Curr Hypertens Rev; 2024; 20(1):10-22. PubMed ID: 38318826
[TBL] [Abstract][Full Text] [Related]
8. Mice heterozygous for the xanthine oxidoreductase gene facilitate lipid accumulation in adipocytes.
Murakami N; Ohtsubo T; Kansui Y; Goto K; Noguchi H; Haga Y; Nakabeppu Y; Matsumura K; Kitazono T
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):44-51. PubMed ID: 24158515
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
10. The double faced role of xanthine oxidoreductase in cancer.
Chen MM; Meng LH
Acta Pharmacol Sin; 2022 Jul; 43(7):1623-1632. PubMed ID: 34811515
[TBL] [Abstract][Full Text] [Related]
11. Uric acid secretion from adipose tissue and its increase in obesity.
Tsushima Y; Nishizawa H; Tochino Y; Nakatsuji H; Sekimoto R; Nagao H; Shirakura T; Kato K; Imaizumi K; Takahashi H; Tamura M; Maeda N; Funahashi T; Shimomura I
J Biol Chem; 2013 Sep; 288(38):27138-27149. PubMed ID: 23913681
[TBL] [Abstract][Full Text] [Related]
12. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
[TBL] [Abstract][Full Text] [Related]
13. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
[TBL] [Abstract][Full Text] [Related]
14. Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 health examination registry.
Kurajoh M; Fukumoto S; Emoto M; Murase T; Nakamura T; Ishihara T; Go H; Yamamoto K; Nakatani S; Tsuda A; Yamada S; Morioka T; Mori K; Imanishi Y; Inaba M
Clin Chem Lab Med; 2020 Apr; 58(5):780-786. PubMed ID: 31085741
[TBL] [Abstract][Full Text] [Related]
15. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.
Kelley EE
Arch Toxicol; 2015 Aug; 89(8):1193-207. PubMed ID: 25995007
[TBL] [Abstract][Full Text] [Related]
16. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.
Okuyama T; Shirakawa J; Nakamura T; Murase T; Miyashita D; Inoue R; Kyohara M; Togashi Y; Terauchi Y
Sci Rep; 2021 Feb; 11(1):3768. PubMed ID: 33580173
[TBL] [Abstract][Full Text] [Related]
17. Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis.
Aibibula Z; Ailixiding M; Iwata M; Piao J; Hara Y; Okawa A; Asou Y
Biochem Biophys Res Commun; 2016 Mar; 472(1):26-32. PubMed ID: 26903297
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
19. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Schuchardt M; Herrmann J; Tolle M; van der Giet M
Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
[TBL] [Abstract][Full Text] [Related]
20. Unexpected high plasma xanthine oxidoreductase activity in female subjects with low levels of uric acid.
Furuhashi M; Mori K; Tanaka M; Maeda T; Matsumoto M; Murase T; Nakamura T; Koyama M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2018 Nov; 65(11):1083-1092. PubMed ID: 30068899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
